Treatment with Biologic Drugs in Pediatric Beh çet’s Disease: A Comprehensive Analysis of the Published Data
ConclusionsThe presented systematic literature search revealed that TNF- α inhibitors followed by interferons were the most frequently used biologic drugs in pediatric BD. Both group of biologic treatments appeared to be effective and have an acceptable safety profile in pediatric BD. However, controlled studies are required for analyzing indications for biologic treatm ents in pediatric BD. (Source: BioDrugs)
Source: BioDrugs - June 29, 2023 Category: Drugs & Pharmacology Source Type: research
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases
AbstractJanus kinase inhibitor (JAKi) medications are small-molecule drugs that affect intracellular signal transduction. They are highly effective oral medications that have been approved for the treatment of various rheumatic diseases, with rheumatoid arthritis being a key example of an autoimmune rheumatic disease. JAKi are oral-route medications that are alternatives to injectable biologic therapies, launched in the late 1990s. While most safety concerns with JAKi are similar to the biologics, there are many differences. New data on comparative safety of JAKi versus tumor necrosis factor inhibitors (TNFi) were recent...
Source: BioDrugs - June 23, 2023 Category: Drugs & Pharmacology Source Type: research
Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
ConclusionGiven the small numbers of IARs that occurred with the home infusions, of which only one was severe, we conclude that alglucosidase alfa can be administered safely in the home situation, provided the appropriate infrastructure is present. (Source: BioDrugs)
Source: BioDrugs - June 16, 2023 Category: Drugs & Pharmacology Source Type: research
The Role of Biologics in the Treatment of Chronic Rhinosinusitis
This article explores the evidence behind biologics for CRSwNP, the guidance on their use and the health economic factors influencing their position amongst the established therapeutic options for this common chronic condition. (Source: BioDrugs)
Source: BioDrugs - June 15, 2023 Category: Drugs & Pharmacology Source Type: research
Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases
We describe several examples of the use of BE and PE to improve rare and common disease phenotypes in preclinical models and human patients, with an emphasis on in vivo editing efficacy, safety, and delivery method. We also discuss recently developed delivery methods for these technologies that may be used in future clinical settings. (Source: BioDrugs)
Source: BioDrugs - June 14, 2023 Category: Drugs & Pharmacology Source Type: research
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
AbstractMultidrug-resistant (MDR) bacteria are considered a health threat worldwide, and this problem is set to increase over the decades. The ESKAPE, a group of six pathogens includingEnterococcus faecium,Staphylococcus aureus,Klebsiella pneumoniae,Acinetobacter baumannii,Pseudomonas aeruginosa andEnterobacter spp. is the major source of concern due to their high death incidence and nosocomial acquired infection. Host defence peptides (HDPs) are a class of ribosomally synthesised peptides that have shown promising results in combating MDR, including the ESKAPE group, in- and outside bacterial biofilms. However, their poor...
Source: BioDrugs - June 10, 2023 Category: Drugs & Pharmacology Source Type: research
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart
ConclusionThe biological characterization studies of BGL-ASP demonstrated high binding and functional similarity to NovoRapid®. (Source: BioDrugs)
Source: BioDrugs - June 7, 2023 Category: Drugs & Pharmacology Source Type: research
Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults
ConclusionIn this study, we demonstrated for the first time that a single subcutaneous injection of GB223, from 7 to 140 mg, is safe and well tolerated in healthy Chinese subjects. GB223 has a nonlinear pharmacokinetic profile, and sex was a potential covariate that may affect the absorption rate of GB223.Clinical Trial RegistrationNCT04178044 and ChiCTR1800020338 (Source: BioDrugs)
Source: BioDrugs - June 6, 2023 Category: Drugs & Pharmacology Source Type: research
